| Trial ID: | L0370 |
| Source ID: | DRKS00027573
|
| Associated Drug: |
HepaLipa
|
| Title: |
HepaLipa-Study: Observing the influence of an IL-17 inhibition on liver steatosis and inflammation. - HepaLipa
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
;K76.0 - Fatty (change of) liver, not elsewhere classified;K75.8 - Other specified inflammatory liver diseases
|
| Interventions: |
Intervention 1: Patients with psoriasis, psoriatic arthritis or ankylosing spondylitis for whom a new biological therapy is started undergo hepatologic examination (Fib4, NAFLD fibrosis score, transient elastography, CK18, hyaluronic acid) and immunologic
|
| Outcome Measures: |
Observation of the immune response (Th17 / Treg ratio) and the course of NAFLD (Fib4 Score, NAFLD-Fibrosis Score, CK18, hyaluronic acid) under therapy with IL-17 antagonists.nan
|
| Sponsor/Collaborators: |
Universit??tsklinikum Freiburg, Department Innere Medizin
|
| Gender: |
All
|
| Age: |
18 Yearsno maximum age
|
| Phases: |
Not applicable
|
| Enrollment: |
160
|
| Study Type: |
interventional
|
| Study Designs: |
Allocation: Other;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Other;
|
| Start Date: |
14/01/2022
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Germany
|
| URL: |
http://www.drks.de/DRKS00027573
|
